Shivam Kumar Kori

Mr. Shivam Kumar Kori

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 October 2023 in Preprints.org
Verified
Preprint
Open access
PDF file
PNPriyanshu Nema
Priyanshu Nema
SAShivangi Agarwal
Shivangi Agarwal
SKShivam Kumar Kori
Shivam Kumar Kori
AKAJAY KUMAR
AJAY KUMAR
VKVarsha Kashaw
Varsha Kashaw
SKSushil Kashaw
Sushil Kashaw
(1) Background: Type-2 Diabetes (T2DM) is a long-term medical disorder characterized by Insulin deficiency and high blood glucose levels. Among other medication to cure T2DM, the review of the literature found that various Pyrimidine derivative act as an agonist for G-protein-coupled receptor 119 (GPR119) was proposed to control blood glucose levels by enhancing the function of pancreatic beta-cells and its mechanism of action with fewer adverse effects.; (2) Methods: In the present research work, in-silico investigations were carried out to investigate the potential of Pyrimidine analogue as an agonists to the protein target GPR119 receptor. We performed exhaustive molecular modelling and protein modelling methodologies such as homology mod-elling, molecular docking along with various drug designing tools such as 3D-QSAR and pharmacophore mapping to ascertain the design of better GPR119 agonists.; (3) Results: On the basis of in-depth computa-tional studies, we designed new pyrimidine moiety and analyzed them for GPR-119 receptor agonist and fur-ther explored the ADME properties. Designed compounds found to exhibit better predicted activities as com-pared to reference compound; (4) Conclusions: The current research on pyrimidine derivatives, using molec-ular docking, 3D-QSAR and Pharmacophore mapping demonstrated that the obtained computational model has significant properties and the designed molecules and Dataset from this model, produced antidiabetic compound against the target GPR119 i.e., compound 1S, 1Z and 1D with the docking score of −11.696, -9.314 and -8.721 respectively. The pharmacokinetics and drug-likeness studies revealed that these compounds may be the future candidate for the treatment of diabetes acting via GPR119 agonist mechanism.

28 September 2026 in Proceedings of the Indian National Science Academy
Verified
Journal Article
Closed access
PDF file
SKShivam Kumar Kori
Shivam Kumar Kori
SKSumit Kolte
Sumit Kolte
NKNishit Deepansh Kumar
Nishit Deepansh Kumar
ADAbhay Dubey
Abhay Dubey
TKTukaram Karnawad
Tukaram Karnawad
SKSushil Kashaw
Sushil Kashaw